CooperCompanies Announces 2025 Q4 and Full Year Revenue Growth, Names New Board Chair
Published on December 5, 2025
SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO), a medical device company, yesterday announced financial results for its fiscal fourth quarter and full year ended October 31, 2025. The company reported Q4 2025 revenue of $1,065.2 million, up 5 percent, or 3 percent organically, compared with the same period last year. CooperVision (CVI) revenue increased 5 percent year-over-year to $709.6 million in Q4, led by the sale of its toric and multifocal contact lenses, which saw 7 percent growth. CooperSurgical (CSI) revenue was up 4 percent in Q4 to $355.6 million, led by 6 percent growth in its office and surgical segment, according to the announcement.